Sophia B. Georghiou

Geneve, GE, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

Correction: Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials.

Correction: Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials.

Journal: Frontiers in antibiotics
Published: November 19, 2025

Molecular diagnostic tests for isoniazid-resistant tuberculosis: a scoping review.

Molecular diagnostic tests for isoniazid-resistant tuberculosis: a scoping review.

Journal: The Lancet. Microbe
Published: June 22, 2025

The ahpC c-54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis.

The ahpC c-54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis.

Journal: Antimicrobial agents and chemotherapy
Published: April 22, 2025

Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials.

Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials.

Journal: Frontiers in antibiotics
Published: February 04, 2025

Targeted next-generation sequencing for drug-resistant tuberculosis diagnosis: implementation considerations for bacterial load, regimen selection and diagnostic algorithm placement.

Targeted next-generation sequencing for drug-resistant tuberculosis diagnosis: implementation considerations for bacterial load, regimen selection and diagnostic algorithm placement.

Journal: BMJ global health
Published: January 24, 2025

Triage test for all-oral drug-resistant tuberculosis (DR-TB) regimen: a phase IV study to assess effectiveness, feasibility, acceptability and cost-effectiveness of the Xpert MTB/XDR assay for rapid triage and treatment of DR-TB.

Triage test for all-oral drug-resistant tuberculosis (DR-TB) regimen: a phase IV study to assess effectiveness, feasibility, acceptability and cost-effectiveness of the Xpert MTB/XDR assay for rapid triage and treatment of DR-TB.

Journal: BMJ open
Published: November 28, 2024

Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows.

Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows.

Journal: The Lancet. Infectious diseases
Published: June 13, 2024

The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis-lessons from the South African experience.

The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis-lessons from the South African experience.

Journal: The Lancet. Infectious diseases
Published: November 03, 2023

Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles.

Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles.

Journal: The Lancet. Microbe
Published: October 23, 2023

Designing molecular diagnostics for current tuberculosis drug regimens.

Designing molecular diagnostics for current tuberculosis drug regimens.

Journal: Emerging microbes & infections
Published: February 08, 2023

In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis.

In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis.

Journal: Scientific reports
Published: July 05, 2022

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies.

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies.

Journal: Clinical microbiology reviews
Published: March 21, 2022
Showing 1-12 of 39

Last Updated: 09/26/2026